The combination of Gefitinib/simvastatin with anti-PD-L1-modified liposomes or with Vorinostat (histone deacetylase inhibitor) demonstrated better antitumor effect by repolarization of macrophages (inhibition of CD206, ARG-1 expression and activation of CD86, iNOS expression, and ROS production) and inhibition of revascularization (downregulation of VEGF, HIF-1a and CD31 expression) in lung cancer cell lines (195, 196). The gene discussed is CD86; the disease is lung cancer.